Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/ ...
Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they ...
Nuvalent seeks FDA approval of neladalkib for TKI-pretreated advanced ALK-positive NSCLC, leveraging ALKOVE-1 results demonstrating activity in extracranial disease and brain metastases. ALKOVE-1 ...
CatalYm today announced that the first patient has been dosed in the GDFATHER-HCC-01 trial (NCT07219459). The trial evaluates ...
The Print on MSN
MIT study answers why some cancer treatments fail. Most tumours have active backdoor pathways
Some cancer treatments fail not because the drugs were ineffective, but because tumours design a network to evade them.
The post HYD Pioneers New Research Revealing Systemic Role of Deuterium-Depleted Water in Cancer Therapy appeared first on ...
“Interestingly, BIRC5 and MCL-1 have both been reported to be over-expressed and strongly correlated with progression and ...
Neladalkib produced a 31% ORR in 253 TKI-pretreated patients and a 46% ORR in lorlatinib-naive patients, supporting utility ...
8don MSN
Why a potential anti-cancer agent stalled in trials: New enzyme insights may boost yield and purity
Researchers at the University of Bayreuth have, for the first time, deciphered key steps in the biosynthetic mechanism of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results